Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. by Seymour, L, Ferry, DR, Anderson, D, Hesslewood, S, Julyan, P, Poyner, R, Doran, J, Young, A, Burtles, S, Kerr, D

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. by Seymour, L, Ferry, DR, Kerr, D, Rea, D, Whitlock, M, Poyner, R, Boivin, C, Hesslewood, S, Twelves, C, Blackie, R, Schatzlein, A, Jodrell, D, Bissett, D, Calvert, H, Lind, M, Robbins, A, Burtles, S, Duncan, R, Cassidy, J